Targeting cancer.

There used to be a time when we thought that there might be a cancer gene that if activated can cause cancer. Then, it became obvious that there might be a gene that if inactivated sets off cancer. Since the early days over a dozen receptors have been discovered that activate a cancer pathway (CD28, OX40, GITR, CD137, CD27, HVEM) or are inhibitory receptors (CTLA-4, PD-1, TIM-3, BVTLA, VISTA, LAG-3). There are more.

A comprehensive article on studies involving these factors is published here:

http://www.partnering360.com/dynfiles/feature/upload/comp_23381/Cancer_Immunotherapies_Report.pdf

For a while, the stocks of companies dealing with these studies have been high fliers, but lately, they have been clobbered. NVAX had dropped 21% yesterday, ADX went from 20 to 10 in a week and INO fell from 7.5 to 5.5 in 3 days.

The probability of success of immunotherapy has not changed. What has changed is the Stock Market as we are preparing for a severe drop.